“Jaan hai to Jahan Hai”. (If) there’s life, then there’s the world.
If there’s anything worth using technology, it’s for keeping ourselves alive and healthy. With the development in technology, healthcare in India is showing a gradual progress. The medical industry has undoubtedly benefited hugely from technological advancements and is the most promising market for businesses across the globe. There are millions of opportunities to create an evolving business by tackling the major medical challenges of the mass population. Numerous startups and companies are looking to HealthTech to offer life-changing products that harness innovation to enhance quality of care. But what are the latest developments in the works, and which companies are fuelling them?
1). Scalp cooling to prevent chemotherapy-related hair loss
Chemotherapy-induced temporary hair loss is one of the most common and distressing side-effects of cancer therapy. The Scalp cooling system has the potential to reduce cellular uptake of chemotherapy agents and decrease the chances of hair follicles experiencing damage from chemotherapy. During the clinical trial, 50.5% of patients were able to preserve their hair using the scalp cooling system. The system was FDA-approved in May 2017 and is starting to become available in hospitals nationwide.
Title: Head cooler
Assignee: Dignitana AB
Publication Date: 11 Aug 2015
Abstract: A head cooler (10) comprises a thermal exchange cap (11) and an outer insulating cover (12) to be arranged on a patient’s head. The cap (11) has a channel system (31, 32) for a cooling fluid forming an inside heat exchange surface to be applied on said head for cooling the head. The thermal exchange cap (11, 60) is adjustable and/or adaptable to compensate for a discrepancy in shape and size between the inside surface of the head cooler (10) and the head. The head cooler (10) may further comprise an eyebrow cooler (140) for cooling the area of the eyebrows. The head cooler (140) is used in medicine. A method for preventing hair loss of a patient is provided by arranging the head cooler (10) on the head of said patient.
2. Centralized medical monitoring system
In a hospital health care monitoring system it is necessary to constantly monitor the patient’s physiological parameters
Title: Medical monitoring system based on sound analysis in a medical environment
Assignee: KONINKLIJKE PHILIPS N.V.
Publication Date: 23 May 2017
Abstract: The invention relates to a medical monitoring system (100) based on sound analysis in a medical environment. A sound level analyzer (SLA, 10) is capable of providing an indicator for perceived levels of sound from a number of sound events, and a data storage modality (DSM, 20) is receiving and storing said indicator for perceived levels of sound and also corresponding information from an associated patient monitoring system (PMS, 60) handling information indicative of a physical and/or mental condition of a patient under influence by sound. A sound event analyzer (SEA, 30) is further being arranged for performing, within a defined time window, an overall sound analysis (ANA, 50) related to physical and/or mental condition of the patient that may be influenced by sound in order to assist or supervise medical personal with respect to the acoustic environment.
3. Enhanced recovery after surgery
Enhanced recovery after surgery (ERAS) protocols are multimodal perioperative care pathways designed to achieve early recovery after surgical procedures by maintaining preoperative organ function and reducing the profound stress response following surgery.
Title: Compositions and methods for enhancing recovery after surgery or an athletic performance
Assignee: Top Doctors Labs (Fairfield, CA, US)
Publication Date: 15 March 2016
Abstract: The invention provides compositions and dosage forms, e.g., in the form of dietary supplements, such as pills, tablets, beverages, or gels, that enhance recovery after surgery or after an athletic performance. An exemplary composition or dosage form comprises about 5000 IU of vitamin A, about 15 mg of vitamin B1, about 34 mg of vitamin B2, about 25 mg of vitamin B3, about 50 mg of vitamin B5, about 20 mg of vitamin B6, about 90 μg of vitamin B12, about 300 mg of vitamin C, about 500 IU of vitamin D, about 60 IU of vitamin E, about 160 μg of vitamin K1, about 5 μg of vitamin K2, about 300 μg of biotin, about 400 μg of folate, about 30 μg of PABA, about 1 mg of boron, about 200 μg of chromium, about 500 μg of copper, about 150 mg of magnesium, about 5 μg of manganese, about 100 μg of molybdenum, about 135 μg of selenium, about 100 μg of vanadium, about 20 mg of zinc, about 150 μg of iodine, about 1.2 mg of pomegranate extract, about 250 mg of bromelain, and about 250 mg of quercetin. Methods for using the compositions and dosage forms for enhancing recovery after surgery or after an athletic performance are also provided herein. The invention also provides kits comprising a composition or dosage form described herein.
4. Targeted breast cancer therapies
Targeted cancer therapies target specific characteristics of cancer cells, or gene mutations that result in tumor development. Targeted therapies as the name specifies specifically target cancer cells and are less likely to harm normal and healthy cells as compared to chemotherapy.
Title: Stable gene targets in breast cancer and use thereof for optimizing therapy
Assignee: Cytognomix Inc. (London, Ontario, CA)
Publication Date: 18 April 2017
Abstract: A method for determining genes in breast cancer that are stable in copy number, expression and sequence in tumors from nearly all patients. Certain stable genes are targets of standard chemotherapy. The effectiveness of therapies that act upon these targets depends on maintaining the stability and integrity of these genes in tumors. Mutations in these targets result in poor response to therapies that target these gene products. In the instant invention, ordinarily stable gene targets are characterized as either normal or mutant for the purpose of determining whether to include or exclude particular drugs as potential treatments.
Title: ADAM22 for use as a prognostic variable, and target for therapy, of a metastatic breast cancer disease
Assignee: Royal College of Surgeons in Ireland (Dublin, IE)
Publication Date: 15 March 2016
Abstract: A method of diagnosing metastatic potential of a breast cancer in an individual with breast cancer is described. The method comprises a step of assaying a breast cancer tumor sample from the patient for expression of A Disintegrin and Metalloproteinase 22, (ADAM22), wherein expression of ADAM22 correlates with increased potential for metastasis compared with a patient who is ADAM22 negative. The invention also describes an agent for use in the treatment of metastatic breast cancer in a patient, in which the agent is selected from leucine-rich, glioma-inactivated protein 1 (LGI1) protein (SEQ ID NO:1) and an LGI1 peptide mimic capable of mimicking the ADAM22 binding activity of LGI1 by binding to the LGI1 binding domain of ADAM22 (SEQ ID NO: 4) and which is capable of inhibiting migration of endocrine resistant breast cancer cells.
Next-generation vaccine platform
It is expected that the medical industry will be seeing an upgrade to the entire vaccine platform to expedite new vaccines while also creating new ways of delivering vaccines.
Title: Multivalent breast cancer vaccine
Assignee: The Cleveland Clinic Foundation (Cleveland, OH, US)
Publication Date: 3 May 2016
Abstract: Compositions and methods for immunization against human breast cancer are disclosed. In one embodiment the multivalent antigenic composition is provided comprising immunogenic polypeptides selected from the group consisting of human α-lactalbumin, αS1 casein, β-casein and κ-casein.
Title: Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines
Assignee: The Catholic University of America (Washington, DC, US)
Publication Date: 3 May 2016
Abstract: Techniques from two basic approaches, structure-based immunogen design and phage T4 nanoparticle delivery, are developed to construct new plague vaccines. The NH2-terminal β-strand of F1 of Yersinia pestis is transplanted to the COOH-terminus of F1 of Yersinia pestis and the NH2-terminus sequence flanking the β-strand of F1 of Yersinia pestis is duplicated to eliminate polymerization but to retain the T cell epitopes. The mutated F1 is fused to the V antigen of Yersinia pestis to thereby form a fusion protein F1mut-V mutant, which produces a completely soluble monomer. The fusion protein F1 mut-V is then arrayed on phage T4 nanoparticles via a small outer capsid protein, Soc, from a T4 phage or a T4-related phage. Both the soluble and T4 decorated F1mut-V provided approximately 100% protection to mice and rats against pneumonic plague evoked by high doses of Yersinia pestis CO92.
6. The emergence of distance health
Physicians are working toward a goal of being able to provide healthcare from the comfort of a patient’s home. This means bringing monitoring devices into the homes and the ability to have a physician tell a patient the type of treatment they need to go through for certain conditions without having to go into the doctor’s office.
Title: System and method for remote tele-health services
Assignee: VIDEOKALL, INC. (Potomac, MD, US)
Publication Date: 8 Dec 2015
Abstract: A tele-health services cabin includes a plurality of vital signs monitoring devices, a cabin management unit, and videoconferencing hardware via which a remote practitioner in a remote medical call center videoconferences with a patient in the cabin to diagnose symptoms of the patient. The cabin management unit includes a processor that controls the cabin, a data input at which patient data is provided from the vital signs monitoring devices, and a transmitter connectable to a communication link for bi-directional communication between the cabin management unit and the medical call center, where the transmitter transmits the patient data to the medical call center. The tele-health services cabin may include a patient chair including a motorized seat back and at least one sensor encapsulated in the seat back. The tele-health services cabin may include a hands-free medical device station. The tele-health services cabin may include an automatic cleaning system.
7. The LDL cholesterol lowering drugs
LDL cholesterol lowering drugs are expected to be disruptors in the next year. The new drugs are expected to lower cholesterol to unprecedented levels.
Title: Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
Assignee: Pivotal Therapeutics Inc. (Woodbridge, Ontario, CA)
Publication Date: 10 Feb 2015
Abstract: A composition and a method of treatment utilizing a combination of statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught.
Title: 3,3′-disubstituted indolines as inhibitors of cholesterol ester transfer protein
Abstract: 3,3′-Disubstituted indoline compounds, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.
8. Hybrid closed-loop insulin delivery system
In 2016, the FDA approved the first hybrid closed-loop insulin delivery system. The system is designed to help manage Type 1 diabetes. It is a fully automated insulin delivery system that connects a continuous glucose monitor with an insulin pump, eliminating the need for people with diabetes having to test and manage their insulin levels themselves.
Title: Method and system for closed-loop control of an artificial pancreas
Assignee: Animas Corporation (West Chester, PA, US)
Publication Date: 24 Oct 2017
Abstract: Methods and systems for controlling an insulin pump in response to glucose measurements are responsive to a base insulin delivery profile and a temporary insulin delivery profile. These can be used, e.g., to control blood glucose level of a subject using a continuous glucose monitor and an insulin infusion pump. During a selected time range, an insulin amount for the pump to supply is determined using the temporary insulin delivery profile. Outside that time range, the insulin amount is determined using the base insulin delivery profile. The temporary insulin delivery profile can specify an exact amount to be supplied (a “hard” profile), a nominal amount to be supplied if doing so does not drive glucose out of a desired zone (“soft”), or a soft profile with a minimum amount of insulin to be delivered (“semi-soft”).